CN110840868B - Application of bromhexine in preparation of anti-cancer drugs - Google Patents
Application of bromhexine in preparation of anti-cancer drugs Download PDFInfo
- Publication number
- CN110840868B CN110840868B CN201910457821.0A CN201910457821A CN110840868B CN 110840868 B CN110840868 B CN 110840868B CN 201910457821 A CN201910457821 A CN 201910457821A CN 110840868 B CN110840868 B CN 110840868B
- Authority
- CN
- China
- Prior art keywords
- bromhexine
- combination
- drug
- lung cancer
- erlotinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of bromhexine in preparing an anti-cancer drug, and test results show that the bromhexine can obviously inhibit the proliferation of lung cancer cells, and when the bromhexine is combined with cisplatin, erlotinib, gefitinib or afatinib, a strong synergistic effect is shown, so that the bromhexine can be used as a drug combination to achieve a better anti-cancer effect.
Description
Technical Field
The invention belongs to the field of medicine preparation, and particularly relates to application of bromhexine in preparation of an anti-cancer medicine.
Background
Lung cancer is one of the most common malignant tumors, the morbidity and mortality are high, and the morbidity is still rising due to the aggravation of atmospheric pollution, smoking and other factors. The lung is also the most frequently occurring metastatic site of other malignancies. The first treatment means for lung cancer and lung metastatic cancer is surgical resection, however, patients with surgical resection chances are less than 30%, and other treatment means commonly used comprise targeted drug therapy, chemotherapy, radiotherapy and the like, and have the defects of easy generation of drug resistance, large side effect and the like although the treatment means has a certain curative effect. The factors of complicated pathogenesis, poor treatment effect, high recurrence and metastasis rate, large treatment side effect, poor accuracy and the like of the lung cancer are main reasons for poor overall treatment effect. Therefore, it is of great research significance to elucidate lung cancer pathogenesis and to study new therapeutic strategies.
Bromhexine is a phlegm-resolving medicament widely applied clinically at present. Bromhexine can crack polysaccharide cellulose in the sputum, reduce the viscosity of the sputum, and also can cause the respiratory tract to secrete mucus type small-molecule mucin, so that the sputum becomes thin. The main indications are patients who are difficult to cough mucus caused by chronic bronchitis, asthma and the like.
Disclosure of Invention
The invention provides an application of bromhexine in preparing anticancer drugs, and experimental results show that the bromhexine has a certain anticancer effect and can be used as a new anticancer drug.
Preferably, the anticancer drug is used for treating lung cancer.
Test results show that the bromhexine can obviously inhibit the proliferation of the lung cancer cells PC-9, A549 and H460, and preferably, the anticancer medicament is used for inhibiting the proliferation of the lung cancer cells PC-9, A549 and H460.
The test result shows that the anticancer drug can also be used for inhibiting the colony formation of NSCLC cells.
Preferably, the anticancer drug comprises an active ingredient;
the active ingredients consist of bromhexine and other anti-lung cancer drugs.
Cell tests show that the bromhexine can be combined with certain specific medicines to obtain a better synergistic effect, and preferably, the other anti-lung cancer medicines are one or more of cisplatin, erlotinib, gefitinib and afatinib.
Preferably, the active ingredients consist of bromhexine and erlotinib;
the anticancer drug is used for inhibiting the proliferation of lung cancer cells H460 and PC-9.
As a further preference, the molar ratio of bromhexine to erlotinib is 1: 0.1-2, and at the moment, the combination of the two has a strong synergistic effect, so that the anticancer effect is obviously improved.
Preferably, the active ingredients consist of bromhexine and cisplatin;
the anticancer drug is used for inhibiting the proliferation of lung cancer cells H460.
As a further preference, the molar ratio of bromhexine to cisplatin is 1: 0.1-2, and at the moment, the combination of the two has a strong synergistic effect, so that the anticancer effect is obviously improved.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention develops the new anticancer application of the phlegm-reducing drug bromhexine, in particular to the application on lung cancer;
(2) the bromhexine and the existing anti-lung cancer drugs are combined, so that a strong synergistic effect can be generated between the bromhexine and the existing anti-lung cancer drugs, the anti-cancer effect is improved, and the dosage of the drugs is reduced.
Drawings
FIG. 1 is a graph of the inhibition of lung cancer cell proliferation by bromhexine in the MTT assay of example 1;
FIG. 2 is a graph of inhibition of colony formation of NSCLC cells by bromhexine in example 2;
FIG. 3 is the synergistic anti-NSCLC activity of the combination of bromhexine and erlotinib in example 3;
FIG. 4 is a graph of the synergistic anti-NSCLC activity of the combination of bromhexine and cisplatin in example 4.
Detailed Description
The invention is further described with reference to the following figures and specific embodiments.
Example 1
Three human non-small cell lung cancer cell strains PC-9, A549 and H460 are selected, and the influence of bromhexine on the proliferation of the lung cancer cells is observed through an MTT (methyl thiazolyl tetrazolium) experiment. Cells are paved into a 96-well plate according to 3000 cells per well, bromhexine (solvent is DMSO) with different drug concentrations is added after the cells adhere to the wall, and 20ul of MTT solution (5mg/ml) per well is added after the drug acts for 48 hours. After further incubation for 4 hours, the culture was terminated and the culture supernatant from the wells was carefully aspirated. Crystals were dissolved by adding 150ul DMSO per well. The light absorption value of each well is measured by an enzyme-linked immunosorbent instrument at 490nm wavelength, and the influence of bromhexine on the proliferation of the lung cancer cells is observed, and the result is shown in figure 1. The results show that: after 48 hours of action, the proliferation of NSCLC cell strains can be inhibited in a dose-dependent manner, wherein the IC50 of PC-9 is the lowest and the drugs are the most sensitive.
Example 2 bromhexine inhibits NSCLC cell colony formation.
Tumor cells can be propagated indefinitely to form cell colonies, and the influence of the compound on cell proliferation can be known through colony formation experiments. Cells are evenly paved in a 6-well plate according to 1000 cells per well, after the cells are attached to the wall, bromhexine (25 mu M,50 mu M,100 mu M and DMSO as a solvent) with different concentrations is added to act on NSCLC cells, the drugs are removed after the NSCLC cells act for 24 hours, fresh culture medium is added for continuous culture, after the cells form macroscopic colonies, 4% paraformaldehyde is fixed and then crystal violet is used for staining, the size and the number of the colonies among the wells are compared, and the result is shown in figure 2. The results show that bromhexine can inhibit the colony formation of the two NSCLC cells in a dose-dependent manner.
Example 3 bromhexine-sensitizing EGFR inhibitors exert anti-NSCLC effects
EGFR-TKIs represented by erlotinib, gefitinib and afatinib are first-line therapeutic drugs for EGFR mutant non-small cell lung cancer. However, patients who are initially sensitive to EGFR-TKIs almost end up developing drug resistance, so that the clinical efficacy and application of the drugs are limited. Through MTT experiments, the bromhexine can be used for sensitizing erlotinib to play an anti-tumor role. We used bromhexine and different concentration gradients of erlotinib (0.5. mu.M, 1. mu.M, 2.5. mu.M, 5. mu.M, 10. mu.M) to act together on lung cancer cells H460 and PC-9, and the results are shown in FIG. 3, where (A) bromhexine and erlotinib, alone or in combination, inhibited H460 cell survival. (B) Bromhexine and erlotinib, alone or in combination, inhibit PC-9 cell survival. Bromhexine (at a concentration of 5. mu.M), E: erlotinib (at concentrations of 0.5. mu.M 1. mu.M 2.5. mu.M 5. mu.M and 10. mu.M, respectively).
For H460 cells, 5 μ M bromhexine in combination with 0.5 μ M erlotinib, drug combination index 0.04527; 5 μ M bromhexine in combination with 1 μ M erlotinib, drug combination index 0.04092; 5 μ M bromhexine in combination with 2.5 μ M erlotinib, drug combination index 0.04212; 5 μ M bromhexine in combination with 5 μ M erlotinib, drug combination index 0.07563; 5 μ M bromhexine in combination with 10 μ M erlotinib had a drug combination index of 0.04235.
For PC-9 cells, 5 μ M bromhexine in combination with 0.5 μ M erlotinib, the drug combination index is 30718; 5 μ M bromhexine in combination with 1 μ M erlotinib, drug combination index 0.29851; 5 μ M bromhexine in combination with 2.5 μ M erlotinib, drug combination index 0.33573; 5 μ M bromhexine in combination with 5 μ M erlotinib, drug combination index 0.41023; 5 μ M bromhexine in combination with 10 μ M erlotinib had a drug combination index of 0.42154.
Wherein, CI which is more than or equal to 0.9 and less than or equal to 1.1 is an overlapping effect, CI which is more than or equal to 0.8 and less than or equal to 0.9 is a low-degree synergistic effect, CI which is more than or equal to 0.6 and less than or equal to 0.8 is a medium synergistic effect, CI which is more than or equal to 0.4 and less than or equal to 0.6 is a high synergistic effect, and CI which is more than or equal to 0.2 and less than or equal to 0.4 is a strong synergistic effect, therefore, the combined drug with a specific proportion can obviously improve the anti-tumor effect of the two drugs, simultaneously reduce the concentration of the drug which takes effect, and reduce the side effect brought by the chemotherapy drugs which are used in large dose. The bromhexine combined with erlotinib was found to significantly inhibit the proliferation of NSCLC cell lines after 48h of action compared to single drugs.
Example 4 bromhexine-sensitizing cisplatin exerts an anti-NSCLC effect
Cisplatin is a first-line drug for the treatment of a variety of solid tumors. Platinum-containing dual-drug chemotherapy is one of the treatment options for patients with advanced non-small cell lung cancer without driver mutations. In addition, cisplatin-based combined chemotherapy is also a main treatment scheme for advanced ovarian cancer, osteosarcoma and neuroblastoma, and is effective on multiple squamous cell carcinoma and transitional cell carcinoma such as head and neck, cervical, esophageal and urinary tumors when combined with ADM, CTX and the like. Through MTT experiments, the bromhexine can sensitize cisplatin to play an anti-tumor role. We used bromhexine and cisplatin (0.5. mu.M, 1. mu.M, 2.5. mu.M, 5. mu.M, 10. mu.M) at different concentration gradients to act together on H460, and the results are shown in FIG. 4, where (A) bromhexine and cisplatin alone or in combination inhibited H460 cell survival. Bromhexine (at a concentration of 5. mu.M), Cis: cisplatin (at concentrations of 0.5. mu.M 1. mu.M 2.5. mu.M 5. mu.M and 10. mu.M, respectively).
For H460 cells, 5 μ M bromhexine in combination with 0.5 μ M cisplatin, at a combination index of 0.11780; 5 μ M bromhexine in combination with 1 μ M cisplatin, at a combination index of 0.06475; 5 μ M bromhexine in combination with 2.5 μ M cisplatin, at a combination index of 0.15718; 5 μ M bromhexine in combination with 5 μ M cisplatin at a combination index of 0.08367; 5 μ M bromhexine in combination with 10 μ M cisplatin, the combination index was 0.05789.
5 μ M bromhexine in combination with 0.5 μ M cisplatin for PC-9 cells at a combination index of 0.26602; 5 μ M bromhexine in combination with 1 μ M cisplatin, at a combination index of 0.23788; 5 μ M bromhexine in combination with 2.5 μ M cisplatin, at a combination index of 0.17607; 5 μ M bromhexine in combination with 5 μ M cisplatin at a combination index of 0.28761; 5 μ M bromhexine in combination with 10 μ M cisplatin, the combination index was 0.26874.
Bromhexine combined with cisplatin was found to significantly inhibit the proliferation of H460 after 48H compared to single drug.
Claims (4)
1. The application of bromhexine in preparing anticancer drugs is characterized in that the anticancer drugs comprise active ingredients;
the active ingredients consist of bromhexine and erlotinib;
the anticancer drug is used for inhibiting the proliferation of lung cancer cells H460 and PC-9.
2. Use of bromhexine in the manufacture of an anticancer drug according to claim 1, wherein the anticancer drug is for the treatment of lung cancer.
3. The use of bromhexine in the preparation of an anticancer agent as claimed in claim 1, wherein the said anticancer agent is used to inhibit the proliferation of the lung cancer cells PC-9, a549 and H460.
4. The use of bromhexine in the preparation of an anticancer agent according to claim 1, wherein said anticancer agent is used to inhibit the colony formation of NSCLC cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910457821.0A CN110840868B (en) | 2019-05-29 | 2019-05-29 | Application of bromhexine in preparation of anti-cancer drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910457821.0A CN110840868B (en) | 2019-05-29 | 2019-05-29 | Application of bromhexine in preparation of anti-cancer drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110840868A CN110840868A (en) | 2020-02-28 |
| CN110840868B true CN110840868B (en) | 2022-06-21 |
Family
ID=69594603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910457821.0A Active CN110840868B (en) | 2019-05-29 | 2019-05-29 | Application of bromhexine in preparation of anti-cancer drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110840868B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115518058A (en) * | 2021-12-29 | 2022-12-27 | 河北医科大学 | Application of N-cycloalkyl substituted aromatic methylamine compound in preparation of antiviral drug, structure and preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523666A (en) * | 2014-11-18 | 2015-04-22 | 高炜炜 | Application of bromhexine hydrochloride to preparing medicines for restraining migration and diffusion of cancer cells |
| CN109568299A (en) * | 2017-09-28 | 2019-04-05 | 复旦大学 | Ambroxol purposes in preparing tumor chemotherapeutic drug Synergistic preparations |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014200705A1 (en) * | 2013-06-14 | 2014-12-18 | Stc.Unm | Treatment of autophagy-related disorders |
-
2019
- 2019-05-29 CN CN201910457821.0A patent/CN110840868B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523666A (en) * | 2014-11-18 | 2015-04-22 | 高炜炜 | Application of bromhexine hydrochloride to preparing medicines for restraining migration and diffusion of cancer cells |
| CN109568299A (en) * | 2017-09-28 | 2019-04-05 | 复旦大学 | Ambroxol purposes in preparing tumor chemotherapeutic drug Synergistic preparations |
Non-Patent Citations (1)
| Title |
|---|
| Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential;Santosh Chauhan et al.;《NATURE COMMUNICATIONS》;20151027;第6卷;第1-15页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110840868A (en) | 2020-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020024834A1 (en) | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | |
| US8691870B2 (en) | Use of isothiocyanates for treating cancer | |
| Cai et al. | The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase IIα and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells | |
| EP3378473A1 (en) | Drug combination having anti-tumor efficacy | |
| CN110840868B (en) | Application of bromhexine in preparation of anti-cancer drugs | |
| KR20100031759A (en) | Treatment of melanoma | |
| EP3412287A1 (en) | Application of phosphodiesterase 4 inhibitor zl-n-91 in preparation of medications for lung cancer proliferation and metastasis | |
| CN110522753A (en) | A kind of new type antineoplastic medicine composition, preparation and application | |
| CN110090217B (en) | Pharmaceutical composition and application thereof in preparation of antitumor drugs | |
| WO2022188491A1 (en) | Tumor chemotherapy pharmaceutical composition | |
| TW202034919A (en) | Use of chiauranib in treating small cell lung cancer | |
| CN115364109B (en) | Pharmaceutical preparation for treating lung cancer | |
| CN107823204B (en) | New application of gemifloxacin | |
| WO2019085827A1 (en) | New uses of desmethylclozapine | |
| JP7311177B2 (en) | Combined use of A-NOR-5α androstane drugs with anticancer drugs | |
| CN112933239A (en) | Application of reagent for activating endogenous PD-1 of tumor cells in preparation of antitumor drugs | |
| CN114642665A (en) | Pharmaceutical composition containing palbociclib and 10-hydroxycamptothecin and application | |
| WO2021023291A1 (en) | Use of proflavine in treatment of lung cancers | |
| CN107519494B (en) | Medicinal composition containing liriope muscari baily saponins C | |
| CN113440519A (en) | Application of mycophenolic acid and derivatives thereof in preparation of drugs for targeted therapy of cancers | |
| CN108586410B (en) | Biflavonoid compound and application thereof | |
| CN115381954B (en) | Combined medicine for treating osteosarcoma | |
| CN110893192A (en) | Pharmaceutical composition for treating nasopharyngeal carcinoma | |
| CN116531389B (en) | Application of VS6766 combined with tripterine and pharmaceutical composition | |
| US11351185B2 (en) | Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Lehe Inventor after: Wang Liangxing Inventor after: Zhao Chengguang Inventor after: Shi Lingxi Inventor after: Chen Siyu Inventor after: Lin Mengsha Inventor after: Zhu Yu Inventor after: Li Jifa Inventor after: Zhu Jiandong Inventor after: Huang Xiaoying Inventor before: Zhao Chengguang Inventor before: Wang Liangxing Inventor before: Yang Lehe Inventor before: Shi Lingxi Inventor before: Chen Siyu Inventor before: Lin Mengsha Inventor before: Zhu Yu Inventor before: Li Jifa Inventor before: Zhu Jiandong Inventor before: Huang Xiaoying |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |